June 4, 2024 — Caristo Diagnostics Limited, a global provider of cardiovascular disease diagnostics and risk prediction, has announced the results of a landmark clinical study published May 30 in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events.

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea, announced that its non-contrast CT imaging analysis solution, Heuron ICH, has received FDA 510(k) clearance.

June 3, 2024 — HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to initiate a US Pivotal Study with its technology.

May 31, 2024 — In the United States there are over 8 million active athletes. Given the rapid expansion of sports cardiology, cardiovascular care teams must understand contemporary care and practice management strategies for all athletes—from the elite to the exercise enthusiast.

May 31, 2024 —